TrialSignal transduction and targeted therapy2024

Envafolimab plus lenvatinib and transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a prospective, single-arm, phase II study.

Yiwen Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.